AP2007004061A0 - Pyrrolopyrazoles, potent kinase inhibitors - Google Patents

Pyrrolopyrazoles, potent kinase inhibitors

Info

Publication number
AP2007004061A0
AP2007004061A0 AP2007004061A AP2007004061A AP2007004061A0 AP 2007004061 A0 AP2007004061 A0 AP 2007004061A0 AP 2007004061 A AP2007004061 A AP 2007004061A AP 2007004061 A AP2007004061 A AP 2007004061A AP 2007004061 A0 AP2007004061 A0 AP 2007004061A0
Authority
AP
ARIPO
Prior art keywords
pyrrolopyrazoles
kinase inhibitors
potent kinase
potent
inhibitors
Prior art date
Application number
AP2007004061A
Other languages
English (en)
Inventor
Djamal Bouzida
Liming Dong
Chuangxing Guo
Original Assignee
Galloway & Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galloway & Company filed Critical Galloway & Company
Publication of AP2007004061A0 publication Critical patent/AP2007004061A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
AP2007004061A 2005-01-10 2005-12-28 Pyrrolopyrazoles, potent kinase inhibitors AP2007004061A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64290005P 2005-01-10 2005-01-10
US73377005P 2005-11-04 2005-11-04
PCT/IB2005/003975 WO2006072831A1 (en) 2005-01-10 2005-12-28 Pyrrolopyrazoles, potent kinase inhibitors

Publications (1)

Publication Number Publication Date
AP2007004061A0 true AP2007004061A0 (en) 2007-08-31

Family

ID=36463340

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2007004061A AP2007004061A0 (en) 2005-01-10 2005-12-28 Pyrrolopyrazoles, potent kinase inhibitors

Country Status (30)

Country Link
US (2) US8067591B2 (ru)
EP (1) EP1838718B1 (ru)
JP (1) JP4250195B2 (ru)
KR (1) KR100919343B1 (ru)
CN (1) CN101115760B (ru)
AP (1) AP2007004061A0 (ru)
AT (1) ATE512972T1 (ru)
AU (1) AU2005323797B2 (ru)
BR (1) BRPI0518509A2 (ru)
CA (1) CA2593428C (ru)
CU (1) CU23778B7 (ru)
CY (1) CY1111752T1 (ru)
DK (1) DK1838718T3 (ru)
EA (1) EA011815B1 (ru)
ES (1) ES2365245T3 (ru)
GE (1) GEP20094785B (ru)
HK (1) HK1114380A1 (ru)
HR (1) HRP20110485T1 (ru)
IL (1) IL184275A0 (ru)
MA (1) MA29141B1 (ru)
MX (1) MX2007008385A (ru)
NO (1) NO20073859L (ru)
NZ (1) NZ556273A (ru)
PL (1) PL1838718T3 (ru)
PT (1) PT1838718E (ru)
RS (1) RS51891B (ru)
SI (1) SI1838718T1 (ru)
TN (1) TNSN07254A1 (ru)
WO (1) WO2006072831A1 (ru)
ZA (1) ZA200705628B (ru)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY151455A (en) 2005-12-21 2014-05-30 Pfizer Prod Inc Carbonylamino pyrrolopyrazoles, potent kinase inhibitors
AP2009004958A0 (en) * 2007-02-07 2009-08-31 Pfizer 3-amino-pyrrolo [3,4-C] pyrazole - 5 (1H, 4H, 6H) carbaldehyde derivatives as PKC inhibitors
UA96618C2 (en) * 2007-02-07 2011-11-25 Пфайзер Инк. 3-amino-pyrrolo[3,4-c] pyrazole- 5 (1h, 4h, 6h) carbaldehyde derivatives as pkc inhibitors
CN101675052A (zh) 2007-04-12 2010-03-17 辉瑞大药厂 作为蛋白酶c抑制剂的3-酰氨基-吡咯并[3,4-c]吡唑-5(1h,4h,6h)甲醛衍生物
ES2392003T3 (es) * 2007-07-25 2012-12-03 Bristol-Myers Squibb Company Inhibidores de la triazina quinasa
FR2928150A1 (fr) 2008-02-29 2009-09-04 Vetoquinol Sa Sa Nouveaux derives 7-substitues de 3-carboxy-oxadiazino-quinolones, leur preparation et leur application comme anti-bacteriens
WO2009130900A1 (ja) * 2008-04-24 2009-10-29 日本曹達株式会社 オキシム誘導体、中間体化合物および植物病害防除剤
EP2145891A1 (en) 2008-07-09 2010-01-20 Vetoquinol S.A. 9-substituted-5-carboxy-oxadiazino-quinolone derivatives, their preparation and their application as anti-bacterials
EP2485727A4 (en) * 2009-10-06 2013-05-01 Afraxis Inc PYRROLOPYRAZOLE FOR THE TREATMENT OF CNS DISEASES
KR101483215B1 (ko) 2010-01-29 2015-01-16 한미약품 주식회사 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체
BR112013012175A2 (pt) 2010-11-17 2019-09-24 Hoffmann La Roche combinação, coadministração, uso e método
KR20140063605A (ko) 2011-07-19 2014-05-27 인피니티 파마슈티칼스, 인코포레이티드 헤테로사이클릭 화합물 및 그의 용도
WO2013113773A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113788A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113719A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds ii
JP2015508752A (ja) 2012-02-03 2015-03-23 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 殺菌性ピリミジン化合物
WO2013113720A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113776A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113778A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
IN2014DN07220A (ru) 2012-02-03 2015-04-24 Basf Se
WO2013113716A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113781A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds i
WO2013113782A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013135672A1 (en) 2012-03-13 2013-09-19 Basf Se Fungicidal pyrimidine compounds
CA2865043A1 (en) 2012-03-13 2013-09-19 Basf Se Fungicidal pyrimidine compounds
BR112014020173A8 (pt) 2012-03-16 2017-07-11 Hoffmann La Roche Métodos para o tratamento de um melanoma, utilizações de um inibidor, composições, conjunto, método de inibição, método de identificação, método de ajuste do tratamento e invenção
ES2612885T3 (es) 2012-09-19 2017-05-19 Novartis Ag Dihidro-pirrolidino-pirimidinas como inhibidoras de cinasa
DK2906555T3 (en) * 2012-10-15 2017-02-06 Pfizer Ireland Pharmaceuticals Process for the preparation of voriconazole and analogs thereof
WO2015036059A1 (en) 2013-09-16 2015-03-19 Basf Se Fungicidal pyrimidine compounds
CN105722833A (zh) 2013-09-16 2016-06-29 巴斯夫欧洲公司 杀真菌的嘧啶化合物
MX2017016030A (es) 2015-06-15 2018-08-01 Ube Industries Derivado de dihidropirrolopirazol sustituido.
CN104926735A (zh) * 2015-06-16 2015-09-23 上海合全药物研发有限公司 4-氯-5-氟-2-甲基嘧啶的工业化制备方法
BR112018012914B1 (pt) 2015-12-22 2023-04-18 SHY Therapeutics LLC Composto, uso de um composto e composição farmacêutica
WO2017144546A1 (en) 2016-02-23 2017-08-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of nasopharyngeal carcinoma
EP3544971B1 (en) 2016-11-22 2022-07-06 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 12 (cdk12) and uses thereof
IL271230B1 (en) 2017-06-21 2024-02-01 SHY Therapeutics LLC Compounds interacting with the RAS superfamily for the treatment of cancer, inflammation, RAS pathology and fibrotic diseases
WO2019204332A2 (en) * 2018-04-16 2019-10-24 The Regents Of The University Of California Pak4 inhibitors and methods of use
EP3956446A1 (en) 2019-04-17 2022-02-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders
WO2021198511A1 (en) 2020-04-03 2021-10-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of sars-cov-2 infection
CN111454278B (zh) * 2020-05-15 2021-03-19 四川大学 Pak1抑制剂及其合成和在制备抗肿瘤药物中的应用
WO2022008597A1 (en) 2020-07-08 2022-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of infectious diseases
JP2024507433A (ja) * 2020-12-31 2024-02-20 シノハブ ファーマシューティカルズ カンパニー リミテッド プラスミン阻害剤、そのための調製方法及びその応用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3423414A (en) 1966-01-13 1969-01-21 Ciba Geigy Corp Pyrazolopyridines
US3526633A (en) 1968-03-06 1970-09-01 American Cyanamid Co Substituted 2,4,5,6-tetrahydropyrrolo(3,4-c)pyrazoles
US3947467A (en) 1973-08-02 1976-03-30 Eli Lilly And Company 3-(5-Nitro-2-imidazolyl) pyrazoles
JPS5163193A (ja) 1974-11-26 1976-06-01 Yoshitomi Pharmaceutical Tetorahidoropirazoropirijinkagobutsuno seizoho
US6013500A (en) 1998-05-21 2000-01-11 The Trustees Of Columbia University In The City Of New York PAK4, a novel gene encoding a serine/threonine kinase
MXPA03001169A (es) 2000-08-10 2003-06-30 Pharmacia Italia Spa Biciclo-pirazoles activos como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que comprenden los mismos.
JP2005537290A (ja) * 2002-07-25 2005-12-08 ファルマシア・イタリア・エス・ピー・エー キナーゼ阻害剤として活性なビシクロピラゾール類、その製造方法、およびそれを含有する薬学的組成物
UA81790C2 (ru) 2002-12-19 2008-02-11 Фармация Италия С.П.А. Замещенные пиролопиразольные производные как ингибиторы киназы
US7141568B2 (en) 2003-07-09 2006-11-28 Pfizer Italia S.R.L. Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them

Also Published As

Publication number Publication date
JP2008526826A (ja) 2008-07-24
ES2365245T3 (es) 2011-09-27
IL184275A0 (en) 2007-10-31
RS51891B (en) 2012-02-29
TNSN07254A1 (en) 2008-12-31
AU2005323797A1 (en) 2006-07-13
US20100222342A1 (en) 2010-09-02
CU20070160A7 (es) 2009-03-16
BRPI0518509A2 (pt) 2008-11-25
CA2593428A1 (en) 2006-07-13
ATE512972T1 (de) 2011-07-15
NO20073859L (no) 2007-10-03
CN101115760A (zh) 2008-01-30
MA29141B1 (fr) 2008-01-02
DK1838718T3 (da) 2011-07-25
EP1838718A1 (en) 2007-10-03
SI1838718T1 (sl) 2011-08-31
PT1838718E (pt) 2011-08-17
EP1838718B1 (en) 2011-06-15
HRP20110485T1 (hr) 2011-07-31
NZ556273A (en) 2010-01-29
KR100919343B1 (ko) 2009-09-25
JP4250195B2 (ja) 2009-04-08
KR20070096007A (ko) 2007-10-01
MX2007008385A (es) 2007-08-21
CY1111752T1 (el) 2015-10-07
AU2005323797B2 (en) 2009-07-09
GEP20094785B (en) 2009-09-25
US8067591B2 (en) 2011-11-29
CU23778B7 (es) 2012-02-15
ZA200705628B (en) 2008-11-26
CA2593428C (en) 2012-04-17
WO2006072831A1 (en) 2006-07-13
PL1838718T3 (pl) 2011-10-31
EA200701257A1 (ru) 2007-12-28
CN101115760B (zh) 2010-11-03
EA011815B1 (ru) 2009-06-30
HK1114380A1 (en) 2008-10-31
US8530652B2 (en) 2013-09-10
US20120264751A1 (en) 2012-10-18

Similar Documents

Publication Publication Date Title
IL184275A0 (en) Pyrrolopyrazoles, potent kinase inhibitors
AP2369A (en) Carbonylamino pyrrolopyrazoles, potent kinase inhibitors.
IL190078A0 (en) Kinase inhibitors
TWI370127B (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
GB2424882B (en) Selective kinase inhibitors
SI2270008T1 (sl) 8-heteroaril-3-alkil-1,3-dihidro-imidazo(4,5-c)kinolin-2-oni kot inhibitorji PI-3 kinaz
ZA200606683B (en) Pyrazolotriazines as kinase inhibitors
HK1117523A1 (en) Substituted benzimidazoles as kinase inhibitors
PL1943243T3 (pl) Inhibitory kinazy
IL183276A0 (en) Kinase inhibitors
EP1968581A4 (en) TETRACYCLIC KINASE INHIBITORS
HK1100141A1 (en) Kinase inhibitors
ZA200805028B (en) Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor Xla inhibitors
ZA200804667B (en) Carbonylamino pyrrolopyrazoles, potent kinase inhibitors
ZA200803287B (en) Kinase inhibitors
IL189985A0 (en) Kinase inhibitors
ZA200706212B (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
EP1940411A4 (en) MACROHETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS